Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Summary

The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of age. This is a 2 part study. In part A, patients will receive Hetrombopag for 8 weeks. In part B, all patients will receive Hetrombopag for 24 weeks.

Timeline

Start

2021-03-29

Primary completion

2024-12-31

Completion

2025-06-17

Publications

• Wu R, Gao J, Liu Y, Yu J, Hu S, Liang H, Jiang H, Zhai X, Zhou M, Hao W, Mei H, Li F, Chen Y, Liu W, Yan M, Li R, Xiong J, Zhu Z, Cheng X, Wang T. Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. J Hematol Oncol. 2026 Apr 8;19(1):24. doi: 10.1186/s13045-026-01790-x.

Drugs

Indications